Medical specialists from Malaysia tagged as investigators in clinical trials studying Polycythemia

Total 5 results

Ahlam Naila Kori, Dr
Seen in:
- Pahang, Kuantan, Hospital Tengku Ampuan Afzan
Trials:
- NCT05499013 (Principal Investigator)
Conditions:
- Polycythemia Vera
Azizan Sharif, Dr
Seen in:
- Johor, Johor Bahru, Hospital Sultanah Aminah
Trials:
- NCT05499013 (Principal Investigator)
Conditions:
- Polycythemia Vera
Chew Lee Ping, Dr
Seen in:
- Sarawak, Kuching, Hospital Umum Sarawak
Trials:
- NCT05499013 (Principal Investigator)
Conditions:
- Polycythemia Vera
Ganesh Kasinathan, Dr
Seen in:
- Terengganu, Kuala Terengganu, Hospital Sultanah Nur Zahirah
Trials:
- NCT05499013 (Principal Investigator)
Conditions:
- Polycythemia Vera
Veena Selvaratnam, Dr
Seen in:
- Selangor, Ampang, Hospital Ampang
Trials:
- NCT05499013 (Principal Investigator)
Conditions:
- Polycythemia Vera

Clinical Trials on Polycythemia

Hospices Civils de Lyon

Not yet recruiting

Blood Viscosity in Polycythemia Patients (POLYVISCO)

Polycythemia Secondary | Polycythemia, Primary

France
PharmaEssentia Japan K.K.

Recruiting

Extension Study of P1101 After Completion of Phase 2 Study in PV Patients or Phase 3 Study in ET Patients

Polycythemia Vera (PV)

Japan
Novartis Pharmaceuticals

Completed

Ruxolitinib for Polycythemia Vera in Patients Resistant to or Intolerant of Hydroxyurea.

Polycythemia Vera (PV)

United States
PharmaEssentia Japan K.K.

Recruiting

A Study to Evaluate P1101 in Japanese PV Patients

Polycythemia Vera (PV)

Japan
PharmaEssentia Japan K.K.

Completed

Efficacy and Safety of P1101 in Polycythemia Vera Patients for Whom the Standard of Treatment is Difficult to Apply

Polycythemia Vera (PV)

Japan
Memorial Sloan Kettering Cancer Center
Eli Lilly and Company; Incyte Corporation

Recruiting

A Study of Ruxolitinib in Combination With Abemaciclib for the Treatment of Myelofibrosis

Myelofibrosis Due to and Following Polycythemia Vera

United States
Northwestern University
National Cancer Institute (NCI); Celgene; The Leukemia and Lymphoma Society

Withdrawn

Durvalumab in Treating Patients With Primary, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis

Primary Myelofibrosis | Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase

United States
Ionis Pharmaceuticals, Inc.

Recruiting

A Study to Evaluate Sapablursen (Formerly ISIS 702843, IONIS-TMPRSS6-LRx) in Patients With Polycythemia Vera

Phlebotomy Dependent Polycythemia Vera

United States, Canada, Hungary, United Kingdom, Australia, Poland
Novartis Pharmaceuticals

Terminated

A Study to Evaluate Safety and Efficacy of Panobinostat in Participants With Primary Myelofibrosis

Primary Myelofibrosis | Post-Polycythemia Vera | Post-Essential Thrombocytopenia

United States
Celgene

Recruiting

An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions (INDEPENDENCE)

Primary Myelofibrosis | Myeloproliferative Disorders | Anemia | Myelofibrosis | Post-Polycythemia Vera Myelofibrosis

France, Belgium, Spain, Australia, Canada, United States, Korea, Republic of, Romania, Japan, Israel, Italy, Austria, China, Czechia, Germany, Greece, Ireland, Poland, United Kingdom, Hong Kong, Hungary, Lebanon, Argentina, Chile, Colombia and more

Medical specialists from Malaysia tagged as investigators in clinical trials studying Polycythemia

Clinical Trials on Polycythemia

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Djibouti

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations